Literature DB >> 9922307

Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.

W K Hirota1, T M Loughney, D J Lazas, C L Maydonovitch, V Rholl, R K Wong.   

Abstract

BACKGROUND & AIMS: Adenocarcinoma of the esophagus and esophagogastric junction (EGJ) is increasing, the earliest lesion being specialized intestinal metaplasia (SIM). This study determined the prevalence and demographic features of patients with SIM, dysplasia, and cancer in the esophagus and EGJ.
METHODS: Two antegrade biopsy specimens were taken distal to the squamocolumnar junction (SCJ) and any tongues of pink mucosa proximal to the SCJ. Patients were categorized endoscopically and histologically as having long-segment (LSBE) or short-segment Barrett's esophagus (SSBE), EGJ-SIM, or a normal EGJ.
RESULTS: Of 889 patients studied, 56 were undergoing esophagoduodenoscopy screening or surveillance and were not included in the prevalence calculation. The overall prevalence of SIM was 13.2%, with 1.6% LSBE, 6.0% SSBE, and 5.6% EGJ-SIM. Dysplasia or cancer was noted in 31% of LSBE, 10% of SSBE, and 6.4% of EGJ-SIM patients (P </= 0.043). Two cancers were associated with LSBE, 1 with SSBE, and 1 with EGJ-SIM. Patients with LSBE and SSBE were predominantly white (P </= 0.001), male (P </= 0. 009), and smokers (P </= 0.004), with LSBE patients having a longer history of heartburn (P </= 0.009). In contrast, patients with EGJ-SIM were similar in gender and ethnicity to the reference group, tended to be older (P </= 0.05), drank less alcohol (P </= 0.02), and had a higher prevalence of Helicobacter pylori infection (P </= 0.05).
CONCLUSIONS: The prevalence of SSBE and EGJ-SIM is similar, but each entity is 3.5 times more prevalent than LSBE. However, the prevalence of dysplasia in LSBE is 2 times greater than in SSBE and 4 times greater than in EGJ-SIM. Demographically, EGJ-SIM patients are different from patients with Barrett's esophagus and have a higher prevalence of H. pylori infection. These data help to explain the increasing incidence of adenocarcinoma of the distal esophagus and EGJ.

Entities:  

Mesh:

Year:  1999        PMID: 9922307     DOI: 10.1016/s0016-5085(99)70123-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  92 in total

1.  [Barrett esophagus: epidemiology, incidence of carcinoma, need for screening].

Authors:  R Arnold; M Wied
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

Review 2.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

Review 3.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

4.  Protagonist: endoscopic surveillance of patients with Barrett's oesophagus.

Authors:  H Barr
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 5.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

Review 6.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 7.  Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia.

Authors:  Douglas B Stairs; Jianping Kong; John P Lynch
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

8.  The Z-line appearance and prevalence of intestinal metaplasia among patients without symptoms or endoscopical signs indicating gastroesophageal reflux.

Authors:  B Wallner; A Sylvan; R Stenling; K G Janunger
Journal:  Surg Endosc       Date:  2001-05-02       Impact factor: 4.584

9.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

10.  Use of methylene blue for detection of specialized intestinal metaplasia in GERD patients presenting for screening upper endoscopy.

Authors:  Marten B Duncan; J David Horwhat; Corrinne L Maydonovitch; Ferdanando Ramos; Ramon Colina; Erich Gaertner; Hyun Yang; Roy K H Wong
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.